Report Company Directory
- Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 by GlobeNewsWire
- Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 by GlobeNewsWire
- Immunovant Announces Pricing of $550 Million Common Stock Financing by GlobeNewsWire
- Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 by GlobeNewsWire
- Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 by GlobeNewsWire
- Vital Signs: Actionable charts by Vermilion Research
- Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients by GlobeNewsWire
- Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 by GlobeNewsWire
- Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 by GlobeNewsWire
- Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 by GlobeNewsWire